C WorldWide Group Holding A S Purchases 45,000 Shares of Glaukos Corporation $GKOS

C WorldWide Group Holding A S grew its position in shares of Glaukos Corporation (NYSE:GKOS) by 27.7% during the third quarter, Holdings Channel reports. The institutional investor owned 207,212 shares of the medical instruments supplier’s stock after purchasing an additional 45,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Glaukos were worth $16,898,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GKOS. AQR Capital Management LLC lifted its holdings in Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Glaukos by 1,405.9% in the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the period. Truist Financial Corp lifted its stake in shares of Glaukos by 138.9% during the 2nd quarter. Truist Financial Corp now owns 7,296 shares of the medical instruments supplier’s stock valued at $754,000 after buying an additional 4,242 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in Glaukos by 7.3% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 11,700 shares of the medical instruments supplier’s stock worth $1,208,000 after buying an additional 800 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 315 shares of Glaukos stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total transaction of $33,075.00. Following the completion of the sale, the chief financial officer owned 50,488 shares in the company, valued at approximately $5,301,240. This trade represents a 0.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the transaction, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at $17,684,125. The trade was a 54.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 329,655 shares of company stock worth $37,752,234. 5.80% of the stock is owned by insiders.

Glaukos Trading Down 1.1%

Shares of GKOS stock opened at $113.37 on Friday. The company has a market capitalization of $6.51 billion, a PE ratio of -73.61 and a beta of 0.70. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $161.78. The business’s fifty day moving average is $114.22 and its 200 day moving average is $97.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of analyst reports. BTIG Research boosted their target price on shares of Glaukos from $123.00 to $131.00 and gave the company a “buy” rating in a report on Wednesday, January 28th. William Blair upgraded Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. UBS Group boosted their price objective on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. The Goldman Sachs Group restated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. lifted their target price on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $132.54.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.